BACKGROUND:Yoga therapy (YT) improves cognitive function in healthy individuals, but its impact on cognitive function among persons with schizophrenia (SZ) has not been investigated. AIMS: Evaluate adjunctive YT for cognitive domains impaired in SZ. METHODS:Patients with SZ received YT or treatment as usual (TAU; n = 65, n = 23, respectively). Accuracy and speed for seven cognitive domains were assessed using a computerized neurocognitive battery (CNB), thus minimizing observer bias. Separately, YT was evaluated among patients with BipolarI disorder (n = 40), Major Depressive Disorder (n = 37), and cardiology outpatients (n = 68). All patients also received routine pharmacotherapy. Patients were not randomized to YT or TAU. RESULTS: Compared with the SZ/TAU group, the SZ/YT group showed significantly greater improvement with regard to measures of attention following corrections for multiple comparisons; the changes were more prominent among the men. In the other diagnostic groups, differing patterns of improvements were noted with small to medium effect sizes. CONCLUSIONS: Our initial analyses suggest nominally significant improvement in cognitive function in schizophrenia with adjunctive therapies such as YT. The magnitude of the change varies by cognitive domain and may also vary by diagnostic group.
RCT Entities:
BACKGROUND: Yoga therapy (YT) improves cognitive function in healthy individuals, but its impact on cognitive function among persons with schizophrenia (SZ) has not been investigated. AIMS: Evaluate adjunctive YT for cognitive domains impaired in SZ. METHODS:Patients with SZ received YT or treatment as usual (TAU; n = 65, n = 23, respectively). Accuracy and speed for seven cognitive domains were assessed using a computerized neurocognitive battery (CNB), thus minimizing observer bias. Separately, YT was evaluated among patients with Bipolar I disorder (n = 40), Major Depressive Disorder (n = 37), and cardiology outpatients (n = 68). All patients also received routine pharmacotherapy. Patients were not randomized to YT or TAU. RESULTS: Compared with the SZ/TAU group, the SZ/YT group showed significantly greater improvement with regard to measures of attention following corrections for multiple comparisons; the changes were more prominent among the men. In the other diagnostic groups, differing patterns of improvements were noted with small to medium effect sizes. CONCLUSIONS: Our initial analyses suggest nominally significant improvement in cognitive function in schizophrenia with adjunctive therapies such as YT. The magnitude of the change varies by cognitive domain and may also vary by diagnostic group.
Authors: Raquel E Gur; Vishwajit L Nimgaonkar; Laura Almasy; Monica E Calkins; J Daniel Ragland; Michael F Pogue-Geile; Stephen Kanes; John Blangero; Ruben C Gur Journal: Am J Psychiatry Date: 2007-05 Impact factor: 18.112
Authors: Marc Bourgeois; Joel Swendsen; Frederick Young; Xavier Amador; Stefano Pini; Giovanni B Cassano; Jean-Pierre Lindenmayer; Chuanchieh Hsu; Larry Alphs; Herbert Y Meltzer Journal: Am J Psychiatry Date: 2004-08 Impact factor: 18.112
Authors: Triptish Bhatia; Joel Wood; Satish Iyengar; Sreelatha S Narayanan; Ram Pratap Beniwal; Konasale M Prasad; Kehui Chen; Robert H Yolken; Faith Dickerson; Ruben C Gur; Raquel E Gur; Smita N Deshpande; Vishwajit L Nimgaonkar Journal: Schizophr Res Date: 2017-08-19 Impact factor: 4.939
Authors: Pramod Thomas; Triptish Bhatia; Deepak Gauba; Joel Wood; Colleen Long; Konasale Prasad; Faith B Dickerson; Raquel E Gur; Ruben C Gur; Robert H Yolken; Vishwajit L Nimgaonkar; Smita N Deshpande Journal: J Psychiatr Res Date: 2013-08-03 Impact factor: 4.791